CordenPharma Switzerland

CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities across Europe and the US.In Switzerland, CordenPharma will invest >€500m to construct a greenfield site for small to large-scale peptide development and manufacturing located within the Basel region in Muttenz.In its Colorado, US site, ongoing expansion will target additional large-scale peptide manufacturing capacity of existing lines as well as a greenfield construction for new production areas.View original content:https://www.prnewswire.co.uk/news-releases/cordenpharma-expands-peptide-platform-with-more-than-500-million-euro-greenfield-facility-construction-in-the-basel-region-of-switzerland-302392408.html